CADTH | Evidence Driven
CADTH | Evidence Driven

Drug Reimbursement Recommendation - glucagon (Baqsimi)

Today, CADTH has issued final recommendations for:

glucagon (Baqsimi)

Indications: Severe hypoglycemic reactions
Recommendation: Reimburse with clinical criteria and/or conditions

For more information

Last Updated : January 24, 2020